

< (10)(2e) @ecdc.europa.eu>; (10)(2e) (10)(2e) < (10)(2e) @ecdc.europa.eu>; (10)(2e)
< (10)(2e) @ecdc.europa.eu>; DL_PHE_Surveillance < (10)(2e) (10)(2e) < (10)(2e) @ecdc.europa.eu>; PHE_Support.Microbiology
< (10)(2e) @who.int' < (10)(2e) @who.int>; (10)(2e) (10)(2e) < (10)(2e) @ecdc.europa.eu>; Country_Cooperation
< (10)(2e) @ecdc.europa.eu>; (10)(2e) @psc.ie' < (10)(2e) @psc.ie>; (10)(2e) @psc.ie'
<(10)(2e)@psc.ie>; (10)(2e) @who.int' <(10)(2e) @who.int>

Subject: To the NFPs and OCPs for Action: Survey on policies for retesting of previously positive individuals when re-exposed

Dear Operational Contact Points for COVID-19 and Influenza,
Dear National Focal Points for Influenza,

Cc: National Coordinators

We hope this email finds you well.

In the past few weeks we have received some questions from a few of you on testing of persons (particularly healthcare workers) who previously tested PCR positive and who are re-exposed to SARS-CoV-2. We would like to ask if you have policies in your country on this issue.

Specifically:

If a person who previously tested PCR positive to SARS-CoV-2 subsequently has an unprotected exposure, would you recommend testing for SARS-CoV-2?

1. If yes, do you recommend testing with (i) PCR, (ii) serology?
 - a. How long after exposure?
 - b. Would you recommend follow-up testing?
 - i. How many days after the first test (i.e. the first test following re-exposure)?
 - c. What are your recommendations for quarantine (initial and once results are available)?
1. Would you have different recommendations depending on the duration since the first positive test (eg if re-exposure was within less than three months vs longer than three months)?
2. How would you manage the re-exposed person if they develop symptoms?
3. Would you manage healthcare workers (or other groups) in a different way from the general population in such a situation?

If you have any testing algorithms, guidance documents, etc please feel free to send them with your replies.

Finally, the evidence base around the risk of reinfection is currently pretty limited – could you please let us know if you have collected, are collecting, or planning to collect data around this issue and briefly describe the methods?

We are planning to develop a document providing guidance on this issue based on an ongoing literature review and will summarize the current approaches based on your replies. Please send us your replies by **Friday 28 August** and feel free to get in touch for any clarifications. Thank you for your collaboration!

With best wishes,

The WHO/Europe and ECDC COVID-19 Teams



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.